Development and Validation of TaqMan Chemistry Probe-Based Rapid Assay for the Detection of Echinocandin-Resistance in Candida auris. [PDF]
J Clin Microbiol, 2023 Candida auris is a multidrug-resistant yeast pathogen causing outbreaks in health care facilities worldwide, and the emergence of echinocandin-resistant C. auris is a concern.
Zhu Y +5 more
europepmc +2 more sources
Echinocandin antifungal drug resistance in Candida species: a cause for concern?
Current Infectious Disease Reports, 2010 The echinocandins, the newest generation of antifungal agents, are inhibitors of β-1,3-D-glucan synthesis, an action that damages fungal cell walls. Despite a relatively broad spectrum of activity, these drugs are rapidly fungicidal against most Candida ...
Maurizio Sanguinetti +4 more
core +5 more sources
Development of Echinocandin Resistance in Candida haemulonii: An Emergent, Widespread, and Opportunistic Fungal Pathogen. [PDF]
J Fungi (Basel), 2023 Echinocandins, used for the prevention and treatment of invasive fungal infections, have led to a rise in breakthrough infections caused by resistant Candida species.
Silva LN +8 more
europepmc +2 more sources
Reshaping Echinocandin Antifungal Drugs to Circumvent Glucan Synthase Point Mutation-Mediated Resistance [PDF]
, 2023 Echinocandins are important antifungal drugs that inhibit the activity of the membrane-bound glucan synthase complex, which is responsible for the synthesis of the fungal cell wall β-(1,3)-glucan.
Moriah, Jospe-Kaufman +3 more
core +2 more sources
mBio, 2021 Fungal infections cause significant mortality and morbidity worldwide, and the limited existing antifungal reservoir is further weakened by the emergence of strains resistant to echinocandins, a first line of antifungal therapy.
Rocio Garcia-Rubio +5 more
doaj +1 more source
Echinocandin resistance: an emerging clinical problem? [PDF]
Curr Opin Infect Dis, 2014 Echinocandin resistance in Candida is a great concern, as the echinocandin drugs are recommended as first-line therapy for patients with invasive candidiasis. Here, we review recent advances in our understanding of the epidemiology, underlying mechanisms, methods for detection and clinical implications.Echinocandin resistance has emerged over the ...
Arendrup MC, Perlin DS.
europepmc +4 more sources
Resistance to echinocandin antifungal agents in the United Kingdom in clinical isolates of Candida glabrata: Fifteen years of interpretation and assessment [PDF]
, 2020 Candidaemia is widely reported as the fourth most common form of bloodstream infection worldwide. Reports of breakthrough cases of candidaemia are increasing, especially in the context of a move away from azole antifungals as prophylactic or first line ...
Lawrance, Lynne M. +3 more
core +1 more source
mBio, 2022 Alanine metabolism has been suggested as an adaptation strategy to oxygen limitation in organisms ranging from plants to mammals. Within the pulmonary infection microenvironment, Aspergillus fumigatus forms biofilms with steep oxygen gradients defined by
Joshua D. Kerkaert +7 more
doaj +1 more source
Epidemiology of Echinocandin Resistance in Candida [PDF]
Current Fungal Infection Reports, 2014 Echinocandins are the newest antifungal agents approved for use in treating Candida infections in the US. They act by interfering with 1,3-β-D-glucan synthase and therefore disrupt cell wall production and lead to Candida cell death. There is no intrinsic resistance to echinocandins among Candida species, and isolates from historic collections archived
Nina T, Grossman +2 more
openaire +2 more sources
Candida parapsilosis isolates carrying mutations outside FKS1 hotspot regions confer high echinocandin tolerance and facilitate the development of echinocandin resistance [PDF]
, 2023 Candida parapsilosis is a significant cause of candidemia worldwide. Echinocandin-resistant (ECR) and echinocandin-tolerant (ECT) C. parapsilosis isolates have been reported in various countries but are rare.
Daneshnia, Farnaz +10 more
core +2 more sources